Neurocrine Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

02.12.22	Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022 (PR Newswire)
08.11.22	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences (PR Newswire)
03.11.22	Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting (PR Newswire)
03.11.22	Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 (PR Newswire)
01.11.22	Neurocrine Biosciences Inc Q3 Profit Increases, beats estimates (RTTNews)
01.11.22	Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance (PR Newswire)
31.10.22	Ausblick: Neurocrine Biosciences informiert über die jüngsten Quartalsergebnisse (finanzen.net)
27.10.22	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia (PR Newswire)
24.10.22	Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 (PR Newswire)
19.10.22	Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference (PR Newswire)
17.10.22	Erste Schätzungen: Neurocrine Biosciences gewährt Anlegern Blick in die Bücher (finanzen.net)
11.10.22	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (PR Newswire)
29.09.22	Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer (PR Newswire)
19.09.22	Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 (PR Newswire)
15.09.22	Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress (PR Newswire)
15.09.22	Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress (PR Newswire)
12.09.22	Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care ... (PR Newswire)
06.09.22	Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (PR Newswire)
04.08.22	Neurocrine Biosciences Inc Q2 Earnings Summary (RTTNews)
04.08.22	Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance (PR Newswire)
20.07.22	Erste Schätzungen: Neurocrine Biosciences öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
14.07.22	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results (PR Newswire)
13.06.22	Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 (PR Newswire)
08.06.22	Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (PR Newswire)
06.06.22	Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala (PR Newswire)
06.06.22	Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022 (PR Newswire)
25.05.22	Neurocrine Biosciences Announces Repurchase of Convertible Notes (PR Newswire)
23.05.22	Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022 (PR Newswire)
13.05.22	Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease (PR Newswire)
04.05.22	Neurocrine Biosciences Inc Q1 Profit Decreases, misses estimates (RTTNews)
04.05.22	Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance (PR Newswire)
03.05.22	Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference (PR Newswire)
03.05.22	Ausblick: Neurocrine Biosciences legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
02.05.22	Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week (PR Newswire)
19.04.22	Erste Schätzungen: Neurocrine Biosciences gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
13.04.22	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results (PR Newswire)
01.04.22	Neurocrine Biosciences Reports Positive Data Of Valbenazine For Chorea In Huntington Disease (RTTNews)
01.04.22	Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022 (PR Newswire)
28.03.22	Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan (PR Newswire)
28.03.22	Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022 (PR Newswire)
24.03.22	Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting (PR Newswire)
21.03.22	Neurocrine Biosciences to Present at Stifel 2022 CNS Days (PR Newswire)
01.03.22	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences (PR Newswire)
11.02.22	Neurocrine Biosciences Inc Q4 Earnings Summary (RTTNews)
11.02.22	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 (PR Newswire)
10.02.22	Ausblick: Neurocrine Biosciences zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
27.01.22	Erste Schätzungen: Neurocrine Biosciences stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
25.01.22	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results (PR Newswire)
06.01.22	Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones (PR Newswire)
03.01.22	Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

mehr

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell
28.08.24		Schwacher Handel: NASDAQ Composite zum Handelsstart schwächer